Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
Applied Therapeutics Price Target Cut to $8.00/Share From $13.00 by Citigroup
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $13.00/Share From $11.00 by Citigroup
Express News | Citigroup Maintains Buy on Applied Therapeutics, Lowers Price Target to $8
Applied Therapeutics Options Spot-On: On November 29th, 52,978 Contracts Were Traded, With 105.7K Open Interest
